Research site

Hartford, Connecticut 6112

3 studies enrolling now · 42 studies all time

What they study most

ASCVD Management, Acute Coronary Syndrome, Acute Coronary Syndromes, Anemia, Asthma, Atherothrombosis, Biliary Tract Cancer, Breast Cancer, Early Breast Cancer, COPD, COVID-19, Carcinoma, Cardiovascular Death

Studies at this site

• A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) — Recruiting now
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy — Recruiting now
• Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS — Recruiting now
• Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa — Running, not enrolling
• Registry of Patients With Hypophosphatasia — Enrolling by invitation
• A Study to Describe the Characteristics, Health Care Interventions and Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment — Completed
• Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. — Completed
• CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring — Stopped early
• Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma — Completed
• Dimethyl Fumarate (DMF) Observational Study — Completed
• Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States — Completed
• Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS — Completed
• Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa — Completed
• Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments — Completed
• Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia — Completed
• Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status — Completed
• Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction — Completed
• A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment. — Withdrawn before enrolling
• Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry — Completed
• 307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects — Completed
• A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants. — Completed
• Phase IV O2 Consumption Study in COPD Patients. — Completed
• A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome — Completed
• An Observational Study of Respiratory Syncytial Virus (RSV) Hospitalizations in Preterm Infants — Completed
• Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma — Completed
• Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) — Completed
• TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer — Stopped early
• JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab — Completed
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children — Completed
• Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin — Completed
• JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events — Stopped early
• Iressa Expanded Access Program (EAP) — Completed
• AZD6765 Severe Major Depressive Disorder (MDD) IV — Completed
• A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome — Completed
• AZD6765 for Treatment Resistant Depression — Completed
• Phase 1 Pharmacokinetics of Intravenous Nexium in Children — Completed
• A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID) — Completed
• Study in Patients With COPD — Completed
• A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD — Completed
• A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD — Completed
• Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders — Completed
• Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects — Completed